China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People’s Republic of China. More Details
No risks detected for CBPO from our risk checks.
Flawless balance sheet and fair value.
Share Price & News
How has China Biologic Products Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CBPO has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CBPO underperformed the US Biotechs industry which returned 32.5% over the past year.
Return vs Market: CBPO underperformed the US Market which returned 17.8% over the past year.
Price Volatility Vs. Market
How volatile is China Biologic Products Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall StShould China Biologic Products Holdings Inc (NASDAQ:CBPO) Focus On Improving This Fundamental Metric?
2 years ago | Simply Wall StDoes China Biologic Products Holdings Inc's (NASDAQ:CBPO) PE Ratio Warrant A Sell?
2 years ago | Simply Wall StHow Did China Biologic Products Holdings Inc's (NASDAQ:CBPO) 6.94% ROE Fare Against The Industry?
Is China Biologic Products Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CBPO ($113.18) is trading below our estimate of fair value ($212.93)
Significantly Below Fair Value: CBPO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CBPO is poor value based on its PE Ratio (29.6x) compared to the US Biotechs industry average (29.5x).
PE vs Market: CBPO is poor value based on its PE Ratio (29.6x) compared to the US market (19.1x).
Price to Earnings Growth Ratio
PEG Ratio: CBPO is poor value based on its PEG Ratio (2.8x)
Price to Book Ratio
PB vs Industry: CBPO is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (3.4x).
How is China Biologic Products Holdings forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CBPO's forecast earnings growth (10.6% per year) is above the savings rate (2.2%).
Earnings vs Market: CBPO's earnings (10.6% per year) are forecast to grow slower than the US market (22.1% per year).
High Growth Earnings: CBPO's earnings are forecast to grow, but not significantly.
Revenue vs Market: CBPO's revenue (9.6% per year) is forecast to grow slower than the US market (9.9% per year).
High Growth Revenue: CBPO's revenue (9.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CBPO's Return on Equity is forecast to be low in 3 years time (9.6%).
How has China Biologic Products Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CBPO has high quality earnings.
Growing Profit Margin: CBPO's current net profit margins (28.7%) are lower than last year (28.9%).
Past Earnings Growth Analysis
Earnings Trend: CBPO's earnings have grown by 12.2% per year over the past 5 years.
Accelerating Growth: CBPO's earnings growth over the past year (1.8%) is below its 5-year average (12.2% per year).
Earnings vs Industry: CBPO earnings growth over the past year (1.8%) exceeded the Biotechs industry -7.1%.
Return on Equity
High ROE: CBPO's Return on Equity (9.3%) is considered low.
How is China Biologic Products Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: CBPO's short term assets ($1.4B) exceed its short term liabilities ($123.9M).
Long Term Liabilities: CBPO's short term assets ($1.4B) exceed its long term liabilities ($41.4M).
Debt to Equity History and Analysis
Debt Level: CBPO is debt free.
Reducing Debt: CBPO had no debt 5 years ago.
Debt Coverage: CBPO has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CBPO has no debt, therefore coverage of interest payments is not a concern.
What is China Biologic Products Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CBPO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CBPO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CBPO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CBPO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CBPO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Joseph Chow (58 yo)
Mr. Joseph Chow serves as Senior Advisor at U.S.-China Green Investment Management Ltd. Mr. Chow serves as Chief Executive Officer at China Biologic Products Holdings, Inc. since August 05, 2019. He served ...
|Chairman & CEO||1.42yrs||no data||0.29% |
|Independent Director||8.58yrs||no data||0.14% |
|Director||6.92yrs||no data||0.073% |
|Independent Director||12.25yrs||no data||0.040% |
|Independent Director||2.25yrs||no data||no data|
|Director||2.75yrs||no data||0.0052% |
Experienced Board: CBPO's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
China Biologic Products Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: China Biologic Products Holdings, Inc.
- Ticker: CBPO
- Exchange: NasdaqGS
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$4.367b
- Shares outstanding: 38.58m
- Website: https://www.chinabiologic.com
Number of Employees
- China Biologic Products Holdings, Inc.
- Jialong International Tower
- 18th floor
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CBPO N||BMV (Bolsa Mexicana de Valores)||Yes||New Common Stock||MX||MXN||Jul 2006|
|CBPO||NasdaqGS (Nasdaq Global Select)||Yes||New Common Stock||US||USD||Jul 2006|
|2CH||DB (Deutsche Boerse AG)||Yes||New Common Stock||DE||EUR||Jul 2006|
|0YWS||LSE (London Stock Exchange)||Yes||New Common Stock||GB||USD||Jul 2006|
China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People’s Repu ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/26 05:17|
|End of Day Share Price||2020/10/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.